drugset / Trial / NCT03115424

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

NCT03115424

Phase 3 Completed 46 enrolled Mayo Clinic Novo Nordisk A/S · collab
RandomizedParallel-groupTriple-blindOther

Summary

Observational studies suggest that bariatric surgery is the most effective intervention for weight loss. Comparative effectiveness of Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) demonstrate that RYGB is significantly superior to SG in terms of weight loss and glycemic control. Both RYGB and SG increase GLP-1 concentrations which directly affect B-cell function. Data has shown that the postprandial rise in GLP-1 might affect feeding behavior after RYGB and to a lesser extent SG, where the increase in GLP-1 is less marked. In this study the investigators propose to randomize subjects undergoing SG to receive either placebo or Liraglutide, a GLP-1 receptor agonist, to compare weight loss and CV risk factors.

Timeline

Start
2017-06-22
Primary completion
2023-10-04
Completion
2024-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 3 mg Subcutaneous

Indications